Abstract:Background:Patients harboring anaplastic lymphoma kinase (ALK) or rearranged during transfection (RET) rearrangements are usually diagnosed at a relatively late stage with nodal and distant metastasis, and rapid progression course of ALK/RET fusion-positive lung cancer were well-known. However, clinical characteristics and course of pre-/minimally invasive lung adenocarcinoma harboring ALK or RET fusions are poorly described. Identifying patients with gene fusions at early stage may offer surgical options that could cure those patients.Methods:We retrospectively included patients with surgically resected pre-/minimally invasive lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations or ALK/RET rearrangements, and further compared the patient clinical characteristics, nodule natural course, and survival outcomes. Radiological characteristics including ground-glass component, cystic airspace, pleural attachment, etc. were specially assessed for this study. EGFR (exons 18-22) was detected by Sanger sequencing and quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the ALK/RET rearrangements. Lung cancer-specific survival (LCSS), relapse-free survival (RFS), and overall survival (OS) were all evaluated.Results:Of 238 patients with pre-/minimally invasive lung adenocarcinomas, 226 patients had EGFR mutations, 7 patients had ALK fusions, and 5 patients had RET fusions. Average age at surgery was 45.3 years for ALK/RET-positive group and 52.6 years for EGFR-positive group (P=0.049). Radiologically, among the 12 patients with ALK/RET fusions, the majority of lesions (10/12) manifested as mixed ground-glass opacities (mGGOs), which was significantly more prevalent when compared with patients with EGFR mutations (83.4% vs. 24.3%, P<0.001). Moreover, a substantial proportion of cystic airspace was found in ALK/RET-positive group but not in EGFR-positive group (66.7% vs. 14.2%, P<0.001). Among four patients with ALK/RET fusions undergoing surveillance over 1 year before surgery, two of them developed rapid radiologic progression. The 5-year LCSS and RFS were 100%, 100% for ALK/RET-positive group, and 100%, 100% for EGFR-positive group, respectively.Conclusions:ALK/RET-positive pre-/minimally invasive lung adenocarcinomas were mostly characterized as mGGOs with cystic airspace developing rapid nodule progression, and no recurrence occurred during long-term follow-up after resection. This provides insights into proper curative surgery timing in the management of patients with gene fusions. However, these findings must be treated with caution and validated in future multi-center studies with larger sample size.

Dissecting the clinicopathologic, genomic, and prognostic significance of anaplastic lymphoma kinase rearrangement in resected lung adenocarcinoma

Dissecting the Clinicopathological, Genomic, and Prognostic Significance of ALK Rearrangement in Resected Lung Adenocarcinoma

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Anaplastic Lymphoma Kinase-Positive Adenocarcinoma of Lung:A Cytopathologic Analysis

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features

Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer]

Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study.

Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.

ALK-rearranged Renal Cell Carcinoma: a Multi-Institutional Study of Nine Cases with Expanding the Morphologic and Molecular Genetic Spectrum

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study

Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( <i> <scp>ALK</scp> </i> )‐rearranged non‐small cell lung cancer

Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals

Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.